GLP-Axis Receptor Agonists: Mechanism Overview
The glucagon-like peptide class works through a cascade of overlapping receptor systems. The foundational mechanism — GLP-1 receptor activation in the hypothalamic arcuate nucleus — slows gastric emptying, reduces caloric intake via central satiety signalling, and improves pancreatic beta-cell function. What distinguishes compounds within this class is the addition of secondary and tertiary receptor targets that compound the weight-loss effect through independent pathways.
Key Compounds and Differentiators
Semaglutide (GLP-1R)
A monoagonist with weekly dosing enabled by fatty acid side-chain albumin binding (half-life ~7 days). The STEP 1 Phase 3 trial (2021, n=1961) demonstrated −14.9% body weight over 68 weeks at 2.4 mg/week. This remains the reference benchmark for the class.
Tirzepatide (GLP-1R + GIPR)
A dual co-agonist synthesized on a novel non-GLP scaffold, providing balanced GIP and GLP-1 receptor activity. GIPR activation in adipose tissue enhances insulin-stimulated glucose uptake and may reduce the GI burden of GLP-1 agonism. SURMOUNT-1 (2022, n=2539): −20.9% at 15 mg over 72 weeks. Approved for obesity indication in 2023.
Retatrutide (GLP-1R + GIPR + GcgR)
A triagonist that adds glucagon receptor activation to the dual mechanism. Glucagon receptor signalling increases hepatic glucose output and activates brown adipose tissue thermogenesis — both energy-expenditure pathways independent of appetite suppression. Phase 2 (2023, n=338): −28.7% at 24 mg over 48 weeks — the highest recorded in any pharmacological weight-loss trial.
Cagrilintide (Amylin Analogue)
Cagrilintide targets the amylin receptor system, a separate satiety pathway from GLP-1. It slows gastric emptying via a distinct CNS mechanism and complements GLP-1 agonists when co-administered. The CagriSema combination (Cagrilintide + Semaglutide, SCALE NEXT Phase 2) showed −15.6% at 32 weeks with attenuated GI side-effect burden relative to equivalent-dose semaglutide alone.
AOD9604
A fragment of human growth hormone (hGH 177–191) studied for its lipolytic properties with minimal IGF-1 pathway activation. Evidence remains largely preclinical; it does not share the GI mechanism profile of GLP compounds.
Evidence Quality Summary
| Compound | Peak Trial Data | Phase | Evidence Grade |
|---|---|---|---|
| Semaglutide | −14.9% / 68 wk | Approved | A |
| Tirzepatide | −20.9% / 72 wk | Approved | A |
| Retatrutide | −28.7% / 48 wk | Phase 2 | B+ |
| Cagrilintide+Sema | −15.6% / 32 wk | Phase 2 | B |
| AOD9604 | Preclinical lipolysis | Phase 2 (halted) | C |
Typical Research Protocols
All GLP-axis compounds require structured dose escalation — generally 4-week increments from the minimum effective dose — to allow GI adaptation. Escalation schedules from STEP and SURMOUNT trials are the reference templates. Co-administration of BPC-157 is common to address gastroprotective concerns during escalation.
What to Watch For
Muscle mass preservation during extended deficits is the primary confounder in GLP research. DEXA or BIA tracking is standard. GH secretagogue co-administration (Ipamorelin/CJC-1295) is frequently included in protocols specifically to counteract lean tissue losses during aggressive recomposition.